atai Life Sciences (ATAI) company Recognify Life Sciences has reported that its Phase IIb trial of oral compound, inidascamine, to treat cognitive impairment associated with schizophrenia (CIAS) ...

On 31 March, at the American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago, US, the findings from the PURSUIT Phase IIb clinical trial were presented. The study evaluated the ...